{"title": "Albumin-Augentropfen zur Behandlung von Augenoberfl\u00e4chenerkrankungen", "author": "J D Unterlauft; M Kohlhaas; I Hofbauer; K Kasper; G Geerling; Gerd Geerling", "url": "https://www.academia.edu/50193414/Albumin_Augentropfen_zur_Behandlung_von_Augenoberfl%C3%A4chenerkrankungen", "hostname": "academia.edu", "description": "Albumin-Augentropfen zur Behandlung von Augenoberfl\u00e4chenerkrankungen", "sitename": "Springer Nature", "date": "2009-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Academia.edu uses cookies to personalize content, tailor ads and improve the user experience.\nBy using our site, you agree to our collection of information through the use of cookies.\nTo learn more, view our\n[Privacy Policy.](https://www.academia.edu/privacy)\nAcademia.edu no longer supports Internet Explorer.\nTo browse Academia.edu and the wider internet faster and more securely, please take a few seconds to\n[upgrade your browser](https://www.academia.edu/upgrade-browser).\n2009, Der Ophthalmologe\n2008, Der Ophthalmologe\n2008, Der Ophthalmologe\n2008, Der Ophthalmologe\n2008, Der Ophthalmologe\n2009, Der Ophthalmologe\n2007, Ophthalmologe\nHintergrund In den letzten Jahren wurden gewaltige Fortschritte im Verst\u00e4ndnis neovaskul\u00e4rer Erkrankungen des Auges gemacht. Neue antiangiogene Medikamente habe in die Therapie der AMD und der diabetischen Retinopathie Einzug gehalten. Ziel dieser Arbeit ist es, aktuelle und zuk\u00fcnftige M\u00f6glichkeiten der lokalen antiangiogenen Therapie an Hornhaut, Bindehaut und Vorderkammer aufzuzeigen. Methoden Literatur\u00fcbersicht aus PUBMED und eigene klinische und experimentelle Daten. Ergebnisse Es gibt erste Erfolg versprechende Erfahrungen mit topischen Inhibitoren der Angiogenese (v. a. Bevacizumab) an der Hornhaut und Bindehaut sowie beim intrakameralen Einsatz. Schlussfolgerungen Neue topische antiangiogene Therapieoptionen zum lokalen Einsatz an Hornhaut und Bindehaut sind derzeit bereits off-label verf\u00fcgbar und werden die Therapie angiogener Erkrankungen am vorderen Augenabschnitt deutlich verbessern. Background Recent years have seen tremendous progress in our understanding of the mechanisms of neovascular diseases of the eye. Antiangiogenic treatment options are now widely used in the management of age-related maculopathy (AMD) and diabetic retinopathy. The aim of this article is to highlight some novel methods of local antiangiogenic treatment of the cornea and conjunctiva and in the anterior chamber of the eye. Methods The study took the form of a literature review (PUBMED) and a review of the authors\u2019 own data. Results Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma. Conclusion Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.\n2005\nHintergrund und Fragestellung: Die phototherapeutische Keratektomie mit dem Excimer-Laser (PTK) wird bei rezidivierenden Hornhauterosionen, oberfl\u00e4chlichen Hornhautdystrophien, zentralen Hornhautdegenerationen, oberfl\u00e4chlichen Hornhautnarben und -irregularit\u00e4ten mittlerweile weit verbreitet als Therapie eingesetzt. Beim Gro\u00dfteil der Indikationen gibt es nach Aussch\u00f6pfung konservativer Ma\u00dfnahmen, abgesehen von der Hornhautstichelung bei rezidivierenden Erosionen und der Keratoplastik bei Hornhautdystrophien und Hornhautnarben, keine therapeutischen Alternativen. Bisher wurde die PTK bei\n2007, Ophthalmologe\nHintergrund In den letzten Jahren wurden gewaltige Fortschritte im Verst\u00e4ndnis neovaskul\u00e4rer Erkrankungen des Auges gemacht. Neue antiangiogene Medikamente habe in die Therapie der AMD und der diabetischen Retinopathie Einzug gehalten. Ziel dieser Arbeit ist es, aktuelle und zuk\u00fcnftige M\u00f6glichkeiten der lokalen antiangiogenen Therapie an Hornhaut, Bindehaut und Vorderkammer aufzuzeigen. Methoden Literatur\u00fcbersicht aus PUBMED und eigene klinische und experimentelle Daten. Ergebnisse Es gibt erste Erfolg versprechende Erfahrungen mit topischen Inhibitoren der Angiogenese (v. a. Bevacizumab) an der Hornhaut und Bindehaut sowie beim intrakameralen Einsatz. Schlussfolgerungen Neue topische antiangiogene Therapieoptionen zum lokalen Einsatz an Hornhaut und Bindehaut sind derzeit bereits off-label verf\u00fcgbar und werden die Therapie angiogener Erkrankungen am vorderen Augenabschnitt deutlich verbessern. Background Recent years have seen tremendous progress in our understanding of the mechanisms of neovascular diseases of the eye. Antiangiogenic treatment options are now widely used in the management of age-related maculopathy (AMD) and diabetic retinopathy. The aim of this article is to highlight some novel methods of local antiangiogenic treatment of the cornea and conjunctiva and in the anterior chamber of the eye. Methods The study took the form of a literature review (PUBMED) and a review of the authors\u2019 own data. Results Initial experience with novel inhibitors of angiogenesis, especially bevacizumab, used locally on cornea and conjunctiva is promising. Intracameral injections of VEGF inhibitors can be used to ameliorate neovascular glaucoma. Conclusion Novel antiangiogenic drugs are available for topical use in the anterior segment of the eye (as off-label use) and will improve the management of neovascular diseases affecting cornea and conjunctiva and in the anterior chamber of the eye.\n2013, Der Ophthalmologe\n2011, American Journal of Ophthalmology\nLoading Preview\nSorry, preview is currently unavailable. You can download the paper by clicking the button above.\n2014, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft\nCongenital aniridia manifests in different forms: it can be transmitted in an autosomal dominant way, as sporadic aniridia and as part of several syndromes including WAGR (Wilms tumor, aniridia, genitourinary abnormalities and intellectual disability) and WAGRO syndromes (WAGR and obesity). Furthermore, recent research shows that aniridia associated with alterations in the PAX6 gene often shows further systemic implications (e.g. endocrine, metabolic and neurological pathologies). Therefore, PAX6-related aniridia is more and more considered to be and described as aniridia syndrome or PAX6 syndrome. We present a group of 130 patients with congenital aniridia to enhance awareness of the complexity of the disease. Different to other congenital visual impairments aniridia is characterized by many ocular complications arising during the lifetime which may lead to total blindness (e.g. cataract, aniridic keratopathy and secondary glaucoma). Furthermore, there is a specific surgical risk e...\n2013, Der Ophthalmologe\n2010, Der Ophthalmologe\n2007, Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde\nDer Ophthalmologe\nMoxifloxacin (Vigamox), a 4th-generation fluoroquinolone, covers most isolates causing endophthalmitis. It is safe and effective for systemic and topical use; however, only very limited data are available on prophylactic intracameral administration to prevent endophthalmitis. This study investigated the safety of Vigamox for intracameral application in a cell-culture model. The endothelial toxicity of moxifloxacin (Vigamox) was evaluated in cultured human corneas. Primary human retinal pigment epithelium cells (RPEs), trabecular meshwork cells (TMCs), lens epithelium cells (LECs), and corneal endothelial cells (CECs) were treated with concentrations of Vigamox. Toxic effects were evaluated after 24 h (MTT assay and live-dead assay). By treating TMC, CEC, and RPE cells either with oxidative stress or tumor necrosis factor-alpha (TNF-a), lipopolysaccharide (LPS), and interleukin-6 (IL-6), the effects of moxifloxacin on cellular viability under conditions of inflammation were investiga...\n2017\n2004, Ophthalmologe\n2008, Der Ophthalmologe\n2011, Der Ophthalmologe\n2008, Der Ophthalmologe\nDer Ophthalmologe\n2007, Der Ophthalmologe\n2007, Der Ophthalmologe\nDer Ophthalmologe\nPhotodynamic therapy (PDT) is the standard treatment procedure for many forms of exudative and/or neovascular AMD. Despite therapy, visual acuity often drops to low vision levels. The cost efficiency of treating the eye in which vision is worse is therefore the subject of some controversy. A retrospective case-control study was conducted in all patients who were treated with PDT at the Universit\u00e4tsspital Z\u00fcrich between September 1999 and November 2004. Each patient&amp;amp;amp;amp;#39;s first (with worse vision) and second (with better vision) eyes were compared for situation on presentation and course during treatment. In 117/228 cases (51.3%) visual acuity of the treated eye was better than (or identical to) that of the fellow eye at presentation. Visual acuity before therapy was an average of 0.58+/-0.27 logMAR [Snellen: 0.26 (0.14-0.49)] in the eyes with better visual acuity and 0.69+/-0.4 logMAR [Snellen 0.20 (0.08-0.51)] in the fellow eyes (p=0.015). After therapy there was no significant difference between the patient groups in visual acuity or in the magnitude of any change in visual acuity, or in lesion size or change in lesion size. The outcome of PDT of a second eye (with better visual acuity) is not significantly better than the result obtained in the first eye (the one with worse visual acuity initially).\n2008, Der Ophthalmologe\n2012, Der Ophthalmologe\n2015, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft\nThe spectrum of surgical correction of high myopia has been broadened through surgical implantation of phakic intraocular lenses (pIOL) as a possible alternative to corneal refractive surgery. The purpose of the present study was to evaluate the intraoperative and early postoperative results of patients after the implantation of a posterior chamber implantable collamer (ICL) pIOL to correct high myopia. In particular the study tried to answer the question whether the AquaPORT technology can safely prevent angle closure glaucoma. From March 2012 to November 2013, 24 eyes from 12 patients suffering from a high myopia (- 8.75 \u00b1 4.37 D, maximum - 22.75 D) underwent implantation of a posterior chamber implantable phakic collamer intraocular lens (ICL) with AquaPORT technology in the Homburg/Saar refractive surgery center. The implantable ICL consists of collamer, a collagen copolymer (Staar surgical-V4b/c). The mean age of the patients was 35.5 \u00b1 1.35 years. At 12 months follow-up mean u...\n2007, Der Ophthalmologe\n2014, Der Ophthalmologe\nDer Ophthalmologe\nProliferative vitreoretinopathy (PVR) is a major complication after retinal detachment surgery, but there is no established pharmacotherapy available to control the cell biology of the disease. The aim of this study was to investigate the role of alkylphosphocholines [APCs; erucylphosphocholine (ErPC) was used in this study], novel pharmacologic substances with antiproliferative properties, on intraretinal proliferation initiated by experimental retinal detachment in a well-established in vivo model. Retinal detachments were created in adult pigmented rabbits. ErPC was injected intravitreally on either day 1 or day 2 after detachment. Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) was injected on day 3. Following fixation, retinas were triple-labelled with anti-BrdU (proliferation marker), Isolectin B4 (retinal microglia marker), and anti-vimentin (retinal Mueller glia cell marker). The number of anti-BrdU-labelled cells per millimeter of retina was determined from sections imaged...\n2001, Ophthalmologe\n2008, Der Ophthalmologe\n2007, Der Ophthalmologe\n2006, Albert Neissers (1855-1916) \u2018Stereoscopischer Medicinischer Atlas\u2019 \u2013 Eine aussergewoehnliche fotografische Sammlung aus dem Gebiet der Augenheilkunde\nPictorial illustrations are not only of importance in ophthalmologic teaching, clinical and basic research, but they are highly valued in the field of medicine as a whole; since at least the 17th century book illustrations, wax models, and moulages were commonly used in ophthalmology. However, the advent of photography in the 19th century made the documentation of the body and its multiple diseases much easier. This article now presents one of the first stereoscopic atlases in the field of ophthalmology. It was created between 1895 and 1906 under the direction of the Breslau professor of medicine Albert Neisser in collaboration with a number of influential German-speaking ophthalmologists at various leading medical schools in Germany, Austria, and Switzerland. The place of Neisser\u2019s stereoscopic medical atlas in the history of medicine and in the development of medical photography, during the period when it became published, is here thoroughly described and put in the context of the ground-breaking scientific advances in the century before the last.\n2009, Der Ophthalmologe\n2013, Der Ophthalmologe\n2007, Spektrum der Augenheilkunde\n2014, Der Ophthalmologe\n2002, Ophthalmologe\nHintergrund. Schwere Ver\u00e4tzungen und Verbrennungen des vorderen Augenabschnittes k\u00f6nnen durch irreversible Sch\u00e4digung des Hornhautstammzellpools und daraus resultierender Limbusinsuffizienz zu lange dauernden Wundheilungsst\u00f6rungen, Ersatz des Hornhautepithels durch Bindehautepithel und damit massiver Einsprossung von Gef\u00e4\u00dfen in die Hornhaut f\u00fchren. Bei entsprechender Schwere der Verletzung ist dadurch oft eine ganz wesentliche Visusreduktion die Folge. Die kombinierte Amnion-Limbus-Transplantation wird seit kurzem als neues, Erfolg versprechendes Verfahren zur Hornhautoberfl\u00e4chenrekonstruktion eingesetzt. Patienten und Methode. Es wurden 14 Patienten (Alter von 18\u201362, im Mittel 42 Jahre) mit totaler Limbusinsuffizienz (LI; 13 Ver\u00e4tzungen, 1 Verbrennung) operiert. Nach kompletter oberfl\u00e4chlicher Entfernung des Bindehautpannus und Transplantation von Amnionmembran auf die gesamte Hornhautoberfl\u00e4che wurde in 7 F\u00e4llen zus\u00e4tzlich eine autologe und in 7 F\u00e4llen \u2013 mit beidseitiger LI \u2013 eine homologe Limbustransplantation meist von verwandten Lebendspendern durchgef\u00fchrt und letztere Gruppe anschlie\u00dfend mit Cyclosporin A systemisch immunsupprimiert. Die durchschnittliche Nachbeobachtungszeit betrug 18 Monate. Ergebnisse. In den meisten F\u00e4llen erfolgte eine rasche und stabile Epithelialisierung der Hornhautoberfl\u00e4che. Die anfangs milchig-wei\u00df getr\u00fcbte Amnionmembran klarte in weiterer Folge langsam auf, nach einigen Monaten war diese biomikroskopisch nicht mehr nachweisbar. Bei allen Patienten mit autologer LT zeigte sich mittel- und langfristig eine stabil epithelialisierte Hornhautoberfl\u00e4che, hingegen fanden sich bei 3 von 7 Patienten nach homologer LT mittelfristig erneut rezidivierende Hornhauterosionen. Ein Anstieg der Sehsch\u00e4rfe war in den meisten F\u00e4llen zu verzeichnen, teilweise aber durch irregul\u00e4ren Astigmatismus deutlich limitiert. Letzterer resultierte aus einer Verd\u00fcnnung der Hornhaut durch den initialen Substanzverlust des Hornhautstromas. Schlussfolgerung. Die kombinierte Transplantation von Limbusgewebe und menschlicher Amnionmembran stellt eine Erweiterung der M\u00f6glichkeiten zur Wiederherstellung einer durch Ver\u00e4tzung oder Verbrennung schwer gesch\u00e4digten Augenoberfl\u00e4che dar. Allerdings sind bei den meisten Patienten weitere Schritte wie lamellierende oder perforierende Keratoplastik f\u00fcr eine ausreichende visuelle Rehabilitation notwendig. Background. Severe thermal and chemical burns may result in limbal deficiency leading to persistent epithelial defects, complete conjunctival epithelial ingrowth and vascularisation of the cornea. If sufficiently severe, these burns may lead to very significant visual impairment. Amniotic membrane transplantation with limbal transplantation has recently been proposed as a new method for corneal surface reconstruction. Patients and methods. A total of 14 patients (age 18\u201362 years, mean age 42 years) with limbal deficiency resulting from thermal (n=1) or chemical burns (n=13) underwent surgery. The corneal pannus was completely removed and the amniotic membrane was grafted onto the cornea. Limbal transplantation using autografts obtained from contralateral eyes was performed simultaneously in seven cases. Allografts from a donor were transplanted in seven cases with bilateral involvement. These patients received oral cyclosporin A postoperatively. The mean follow-up time was 18 months. Results. In all cases of limbal autografts the corneal surface showed a complete and stable epithelialisation within a few weeks. Out of seven patients with limbal allografts three displayed recurrent epithelial defects in the long term. The initially semitransparent amniotic membrane became more translucent and biomicroscopically invisible within several months after surgery. There was an increase in visual acuity in most cases, limited mostly by irregular astigmatism due to the initial stromal loss. Conclusions. Amniotic membrane transplantation with limbal transplantation allows reconstruction ocular surfaces severely damaged by chemical or thermal burns. In most cases, however, additional surgical procedures such as lamellar or penetrating keratoplasty are required for adequate visual rehabilitation.\n2010, Ophthalmologe\nHintergrund In Ungarn erh\u00f6ht sich die Zahl der Kontaktlinsentr\u00e4ger stetig. Damit steigt auch die Wahrscheinlichkeit des Auftretens einer Akantham\u00f6benkeratitis. Obwohl immer mehr diagnostische und therapeutische M\u00f6glichkeiten zur Verf\u00fcgung stehen, wird der erreichte Visus durch diese Augeninfektion sehr stark gef\u00e4hrdet. In den letzten Jahren behandelten wir in unserer Klinik immer mehr Patienten mit Akantham\u00f6benkeratitis. In der vorliegenden Studie werden die Symptome der Krankheit sowie die von uns eingesetzten Behandlungen dargestellt und mit den Angaben in der Fachliteratur verglichen. Patienten und Methoden Zwischen 2001 und 2006 haben wir in unserer Klinik 11 Patienten mit Akantham\u00f6benkeratitis behandelt. Ergebnisse Das Durchschnittsalter der Patienten betrug 30 Jahre (16\u201360 Jahre). Die 8 Frauen und 3 M\u00e4nner waren alle Kontaktlinsentr\u00e4ger. Die Infektion trat in 6 F\u00e4llen am rechten Auge, in 5 F\u00e4llen am linken Auge auf. In jedem Fall war schlechte Kontaktlinsenhygenie eine der Ursachen. In 82% der F\u00e4lle trat die Infektion in der Zeit zwischen Juni und September auf. Neben der konservativen Therapie zur Bek\u00e4mpfung der Akantham\u00f6benkeratitis wurde in 6 F\u00e4llen auch eine perforierende Keratoplastik durchgef\u00fchrt. Bei der letzten Kontrolluntersuchung war die beste korrigierte Sehsch\u00e4rfe im Durchschnitt 0,6, aber 4 der Patienten hatten ihre Sehkraft am betroffenen Auge fast vollst\u00e4ndig verloren. Der Verlauf bzw. die Behandlung dauert 6 Monate bis 5 Jahre. Schlussfolgerung Der Fr\u00fchdiagnose kommt hinsichtlich Verlauf der Krankheit eine sehr gro\u00dfe Bedeutung zu. Bestimmte Angaben in der Anamnese (das Tragen von Kontaktlinsen, heftige, ausgepr\u00e4gte Schmerzen, Ringinfiltrat) lassen beim Auftreten einer Keratitis einen m\u00f6glichen Akantham\u00f6benbefall vermuten und die Patienten sind dementsprechend zu behandeln. Eine sofort ausgef\u00fchrte perforierende Keratoplastik f\u00fchrt zu keinem besseren funktionellen Ergebnis. Unsere wichtigsten Aufgaben sind die zielgerichtete Pr\u00e4vention durch effektive Aufkl\u00e4rung der Kontaktlinsentr\u00e4ger \u00fcber die Bedeutung und Methoden der richtigen Kontaktlinsenhygiene. Background With increasing numbers of contact lens wearers, Acanthamoeba infections are also more frequent all over the world and also in Hungary. Despite improved diagnostic and therapeutic possibilities it can still cause serious visual loss. In this study the symptoms, signs, diagnostics and treatment options for Acanthamoeba keratitis (AK) in patients treated in our department are presented and compared to the literature. Patients and methods Between 2001 and 2006 a total of 11 patients were treated in our department for Acanthamoeba keratitis. Results The mean age of the patients was 30 years and the 8 female and 3 male patients were all contact lens wearers. In six cases the right eye was affected and in five cases the left eye. Poor and improper contact lens hygiene was the cause of infection in all cases and 82% of the infections occurred in the summer period between June and September. In addition to long-term conservative treatment, perforating keratoplasty was performed in six cases. After the therapy the best visual acuity was 0.6, but 4 of the patients had a serious visual loss. Follow-up time ranged from 6 months to 5 years. Conclusions Early diagnosis and long-term suitable local therapy are necessary for effective recovery. If the patient wears contact lens and there is severe pain with ring infiltration in the cornea, Acanthamoeba infection should be considered and suitable therapy should be given. Immediately performed perforating keratoplasty does not lead to visual improvement. Prevention by informing the patients about adequate hygiene and use of the cleaning solutions is one of the most important tasks of contact lens specialists.\n2008, Der Ophthalmologe\n2007\n2000, Der Ophthalmologe\n2002, Nervenarzt\n1793 wurde Botulismus, eine \u201cLebensmittelvergiftung\u201d mit potenziell t\u00f6dlichem Verlauf, erstmals in Zusammenhang mit Verzehr von verdorbenen W\u00fcrsten beschrieben, aber erst um 1900 konnte van Ermengen das Exotoxin von Clostridium botulinum (BT) als Ursache dieser Erkrankung erkennen. Weitere biochemische Versuche in der ersten H\u00e4lfte des 20. Jahrhunderts erbrachten schlie\u00dflich Erkenntnisse \u00fcber Wirkmechanismus und Existenz 7 verschiedener Serotypen (BT/A\u2013G). Therapeutisch verwendet wurde BT/A erstmals 1977 in den USA von Scott, der damit Strabismuspatienten behandelte. Die Injektion von minimalen Dosen des Toxins in ausgew\u00e4hlte Muskeln erwies sich in weiterer Folge auch bei Blepharospasmus, Tortikollis und einer Vielzahl anderer noch nicht registrierter Indikationsbereiche als effektiv. Seit den ersten Anwendungen in Deutschland (Roggenk\u00e4mper, Dressler, Benecke) und \u00d6sterreich (Poewe, Auff) in den sp\u00e4ten 80er Jahren kam es zu einer raschen Verbreitung der Therapie durch immer mehr Anwender aus immer mehr Fachrichtungen. Im Forschungsmittelpunkt des vergangenen Jahrzehnts stand die Molekularstruktur des BT und eine m\u00f6gliche Verwendbarkeit weiterer BT-Serotypen zur Umgehung des durch Antik\u00f6rperbildung hervorgerufenem sekund\u00e4ren Therapieversagens. Eine Vermarktung des Serotyps B und die Verf\u00fcgungbarkeit einfacherer Antik\u00f6rpertestverfahren sowie die Zulassung neuer Indikationen werden in naher Zukunft erwartet. Botulism, a potentially lethal form of paralytic food poisoning, was described as early as 1793. Basic research, especially in the late nineteenth and early twentieth centuries, revealed that botulism is caused by exotoxins. Further biochemical work around and after the Second World War gave insight into the molecular structure of seven different serotypes of botulinum toxin (BT/A\u2013G) as well as into its acetylcholine blocking mode of action. In 1977, Scott treated patients with strabism by injecting minute amounts of purified BT/A. In short sequence, BT proved effective in blepharospasm, cervical dystonia, and various off-label indications. In the near future, registration of these new indications, marketing of new serotypes (BT/B), and availability of more practical antibody tests can be expected. The first applications of BT were performed by Roggenkaemper, Dressler, and Benecke in Germany and by Poewe and Auff in Austria. According to a worldwide trend, a rapid expansion regarding BT users and indications followed. Formation of BT competence centers in both countries aims at maintaining high standards in BT research and education.\nozone-therapy.de\n2006, Manfred Knedlik - Georg Schrott (Ed.), Res naturae. Die Oberpf\u00e4lzer Kl\u00f6ster und die Gaben der Sch\u00f6pfung\n2003, Wiener klinische Wochenschrift\nAcanthamoeba keratitis is a corneal disease associated predominantly with contact lens wear. The occurrence of Acanthamoeba keratitis has been rising since 1990 in correlation to the growing number of contact lens wearers. To date approximately 2000 cases have been published around the world. Due to the complicated diagnostics, the elaborate treatment and the usually bad compliance of the patients, Acanthamoeba keratitis unfortunately very often takes a serious progression, which may lead to serious visual loss and perforating keratoplasty. Today, local treatment with a combination of polyhexamethylene biguanide (PHMB) and propamidine isethionate (Brolene) is considered the first line therapy for Acanthamoeba keratitis. Alternatively also a combination of propamidine and chlorhexidine or neomycine achieves good therapeutic results. However, the complicated mode of application consistently remains a problem. The intensive local treatment, i.e. hourly application of therapeutics durin...\n1997, Der Ophthalmologe", "language": null, "image": "http://a.academia-assets.com/images/open-graph-icons/fb-paper.gif", "pagetype": "article", "links": ["https://www.academia.edu/privacy", "https://www.academia.edu/upgrade-browser", "javascript:void(0)", "https://www.academia.edu/signup", "https://www.academia.edu/", "https://www.academia.edu/login", "https://www.academia.edu/signup", "https://www.academia.edu/login", "https://www.academia.edu/signup", "https://www.academia.edu/Jobs", "https://www.academia.edu/about", "https://www.academia.edu/press", "https://medium.com/@academia", "https://www.academia.edu/Directory/People", "https://www.academia.edu/Directory/Papers", "https://www.academia.edu/terms", "https://www.academia.edu/privacy", "https://www.academia.edu/copyright", "https://www.academia.edu/hiring", "https://support.academia.edu/", "https://www.academia.edu/attachments/68270895/download_file?st=MTY5ODQ0Mjc0NiwyMTcuMjM4LjEzNi4xNzYs&s=swp-splash-paper-cover", "https://www.academia.edu/attachments/68270895/download_file?st=MTY5ODQ0Mjc0NiwyMTcuMjM4LjEzNi4xNzYs&s=swp-splash-paper-cover", "https://independent.academia.edu/GerdGeerling", "https://www.academia.edu/49876673/Eigenserum_und_alternative_Blutprodukte_zur_Behandlung_von_Augenoberfl%C3%A4chenerkrankungen", "https://independent.academia.edu/GerdGeerling", "https://www.academia.edu/49876673/Eigenserum_und_alternative_Blutprodukte_zur_Behandlung_von_Augenoberfl%C3%A4chenerkrankungen", "https://www.academia.edu/49876674/Zum_Stand_der_Anwendung_von_Eigenserum_Augentropfen_in_Deutschland", "https://independent.academia.edu/GerdGeerling", "https://www.academia.edu/49876674/Zum_Stand_der_Anwendung_von_Eigenserum_Augentropfen_in_Deutschland", "https://www.academia.edu/19965489/Herstellung_von_Eigenserumaugentropfen_zur_ambulanten_Therapie", "https://independent.academia.edu/BertholdSeitz", "https://www.academia.edu/19965489/Herstellung_von_Eigenserumaugentropfen_zur_ambulanten_Therapie", "https://www.academia.edu/19965494/Arzneimittelrechtliche_Erlaubnis_bei_der_Herstellung_von_Serum_Augentropfen", "https://independent.academia.edu/GerdGeerling", "https://independent.academia.edu/BertholdSeitz", "https://www.academia.edu/19965494/Arzneimittelrechtliche_Erlaubnis_bei_der_Herstellung_von_Serum_Augentropfen", "https://www.academia.edu/49876681/Antiangiogene_Therapie_bei_Pterygiumrezidiven", "https://independent.academia.edu/GerdGeerling", "https://www.academia.edu/49876681/Antiangiogene_Therapie_bei_Pterygiumrezidiven", "https://www.academia.edu/7345644/Antiangiogene_Therapie_am_vorderen_Augenabschnitt", "https://fu-berlin.academia.edu/PhilipZimmermann", "https://www.academia.edu/7345644/Antiangiogene_Therapie_am_vorderen_Augenabschnitt", "https://www.academia.edu/20355945/Health_Technology_Assessment_zur_medizinischen_Wirksamkeit_und_Kosten_Effektivit%C3%A4t_der_Phototherapeutischen_Keratektomiemit_dem_Excimerlaser_bei_rezidivierenden_Erosionen_Hornhautdystrophien_Hornhautdegenerationen_und_oberfl%C3%A4chlichen_Hornhautnarben", "https://independent.academia.edu/PSchnellInderst", "https://www.academia.edu/20355945/Health_Technology_Assessment_zur_medizinischen_Wirksamkeit_und_Kosten_Effektivit%C3%A4t_der_Phototherapeutischen_Keratektomiemit_dem_Excimerlaser_bei_rezidivierenden_Erosionen_Hornhautdystrophien_Hornhautdegenerationen_und_oberfl%C3%A4chlichen_Hornhautnarben", "https://www.academia.edu/7345645/Inhibition_of_angiogenesis_in_the_anterior_chamber_of_the_eye", "https://fu-berlin.academia.edu/PhilipZimmermann", "https://www.academia.edu/7345645/Inhibition_of_angiogenesis_in_the_anterior_chamber_of_the_eye", "https://www.academia.edu/17172505/Lidrandhygiene_bei_Kontaktlinsentr%C3%A4gern_mit_Blepharitis", "https://uni-koln.academia.edu/ArnoHueber", "https://www.academia.edu/17172505/Lidrandhygiene_bei_Kontaktlinsentr%C3%A4gern_mit_Blepharitis", "https://www.academia.edu/47310024/Corneal_Collagen_Cross_linking_With_Riboflavin_and_Ultraviolet_A_Irradiation_in_Patients_With_Thin_Corneas", "https://unisi.academia.edu/StefanoBaiocchi", "https://www.academia.edu/47310024/Corneal_Collagen_Cross_linking_With_Riboflavin_and_Ultraviolet_A_Irradiation_in_Patients_With_Thin_Corneas", "https://www.academia.edu/47039123/_Aniridia_syndrome_clinical_findings_problematic_courses_and_suggestions_for_optimization_of_care_aniridia_guide_", "https://uniklinik-saarland.academia.edu/ProfDrBarbaraK%C3%A4smannKellner", "https://www.academia.edu/47039123/_Aniridia_syndrome_clinical_findings_problematic_courses_and_suggestions_for_optimization_of_care_aniridia_guide_", "https://www.academia.edu/47039100/Behandlung_der_kindlichen_Katarakte", "https://uniklinik-saarland.academia.edu/ProfDrBarbaraK%C3%A4smannKellner", "https://www.academia.edu/47039100/Behandlung_der_kindlichen_Katarakte", "https://www.academia.edu/28246476/Narbenbildung_nach_Hornhautvernetzung_beim_Keratokonus", "https://independent.academia.edu/FRaiskup", "https://www.academia.edu/28246476/Narbenbildung_nach_Hornhautvernetzung_beim_Keratokonus", "https://www.academia.edu/19175618/Moxifloxacin_intravitreal_Eine_sichere_Option_zur_Behandlung_der_bakteriellen_Endophthalmitis", "https://lmu-munich.academia.edu/MarcusKernt", "https://www.academia.edu/19175618/Moxifloxacin_intravitreal_Eine_sichere_Option_zur_Behandlung_der_bakteriellen_Endophthalmitis", "https://www.academia.edu/18153301/_Intracameral_moxifloxacin_a_safe_option_for_endophthalmitis_prophylaxis_In_vitro_safety_profile_for_intraocular_application_", "https://independent.academia.edu/KirstenEibl", "https://lmu-munich.academia.edu/MarcusKernt", "https://www.academia.edu/18153301/_Intracameral_moxifloxacin_a_safe_option_for_endophthalmitis_prophylaxis_In_vitro_safety_profile_for_intraocular_application_", "https://www.academia.edu/40927315/Neue_Forschungen_zur_Medizingeschichte_Beitr%C3%A4ge_des_Rheinischen_Kreises_der_Medizinhistoriker_IV", "https://rwth-aachen.academia.edu/MathiasSchmidt", "https://www.academia.edu/40927315/Neue_Forschungen_zur_Medizingeschichte_Beitr%C3%A4ge_des_Rheinischen_Kreises_der_Medizinhistoriker_IV", "https://www.academia.edu/20580164/Prim_res_intraokul_res_Lymphom", "https://liverpool.academia.edu/SarahCoupland", "https://www.academia.edu/20580164/Prim_res_intraokul_res_Lymphom", "https://www.academia.edu/36599168/Monitoring_von_AMD_Patienten_unter_Anti_VEGF_Therapie", "https://uni-marburg.academia.edu/CarstenMeyer", "https://www.academia.edu/36599168/Monitoring_von_AMD_Patienten_unter_Anti_VEGF_Therapie", "https://www.academia.edu/28246478/Hornhautvernetzung_mit_hypoosmolarer_Riboflavin_L%C3%B6sung_beim_Keratokonus_mit_d%C3%BCnner_Hornhaut", "https://independent.academia.edu/FRaiskup", "https://www.academia.edu/28246478/Hornhautvernetzung_mit_hypoosmolarer_Riboflavin_L%C3%B6sung_beim_Keratokonus_mit_d%C3%BCnner_Hornhaut", "https://www.academia.edu/22915528/Retinale_Pigmentepithelrisse_nach_intravitrealem_Bevacizumab_bei_AMD", "https://independent.academia.edu/NeubauerAljoscha", "https://www.academia.edu/22915528/Retinale_Pigmentepithelrisse_nach_intravitrealem_Bevacizumab_bei_AMD", "https://www.academia.edu/19175674/Bevacizumab_is_not_toxic_to_human_anterior_and_posterior_segment_cultured_cells", "https://lmu-munich.academia.edu/MarcusKernt", "https://independent.academia.edu/ANeubauer2", "https://www.academia.edu/19175674/Bevacizumab_is_not_toxic_to_human_anterior_and_posterior_segment_cultured_cells", "https://www.academia.edu/18751352/Photodynamische_Therapie_bei_altersbedingter_Makuladegeneration_am_schlechteren_und_besseren_Auge", "https://uzh.academia.edu/DanielBarthelmes", "https://www.academia.edu/18751352/Photodynamische_Therapie_bei_altersbedingter_Makuladegeneration_am_schlechteren_und_besseren_Auge", "https://www.academia.edu/19175625/Bevacizumab_wirkt_nicht_toxisch_auf_Zellen_des_menschlichen_Auge", "https://lmu-munich.academia.edu/MarcusKernt", "https://www.academia.edu/19175625/Bevacizumab_wirkt_nicht_toxisch_auf_Zellen_des_menschlichen_Auge", "https://www.academia.edu/18751357/_Photodynamic_therapy_of_AMD_for_the_first_better_sight_and_the_second_worse_sight_eyes_", "https://uzh.academia.edu/DanielBarthelmes", "https://www.academia.edu/18751357/_Photodynamic_therapy_of_AMD_for_the_first_better_sight_and_the_second_worse_sight_eyes_", "https://www.academia.edu/15382777/Bedeutung_der_Cyclosporin_A_Absorption_f%C3%BCr_eine_effektive_immunmodulatorische_Therapie_nach_Hochrisikokeratoplastik", "https://independent.academia.edu/PeterSchlattmann", "https://www.academia.edu/15382777/Bedeutung_der_Cyclosporin_A_Absorption_f%C3%BCr_eine_effektive_immunmodulatorische_Therapie_nach_Hochrisikokeratoplastik", "https://www.academia.edu/47039104/Ausgew%C3%A4hlte_Aspekte_der_Kinderophthalmologie_f%C3%BCr_Nicht_Kinderophthalmologen", "https://uniklinik-saarland.academia.edu/ProfDrBarbaraK%C3%A4smannKellner", "https://www.academia.edu/47039104/Ausgew%C3%A4hlte_Aspekte_der_Kinderophthalmologie_f%C3%BCr_Nicht_Kinderophthalmologen", "https://www.academia.edu/29040118/_Can_the_implantable_collamer_lens_with_AquaPORT_technology_safely_prevent_an_angle_block_Early_experiences_in_the_Homburg_Saar_refractive_surgery_center_", "https://independent.academia.edu/MoatasemElhusseiny", "https://independent.academia.edu/TimoEppig", "https://www.academia.edu/29040118/_Can_the_implantable_collamer_lens_with_AquaPORT_technology_safely_prevent_an_angle_block_Early_experiences_in_the_Homburg_Saar_refractive_surgery_center_", "https://www.academia.edu/17528523/Selbstmedikation_mit_Lokalan%C3%A4sthetika_durch_Glaukompatienten_bei_der_Teletonometrie", "https://independent.academia.edu/FrankTost", "https://www.academia.edu/17528523/Selbstmedikation_mit_Lokalan%C3%A4sthetika_durch_Glaukompatienten_bei_der_Teletonometrie", "https://www.academia.edu/29625909/Pharmakokinetik_intravitreal_applizierter_VEGF_Inhibitoren", "https://uni-bonn.academia.edu/TimKrohne", "https://www.academia.edu/29625909/Pharmakokinetik_intravitreal_applizierter_VEGF_Inhibitoren", "https://www.academia.edu/13425697/Die_Verwendung_des_Excimer_Lasers_in_der_refraktiven_Augenchirurgie", "https://bca-research.academia.edu/WolfgangGreiner", "https://www.academia.edu/13425697/Die_Verwendung_des_Excimer_Lasers_in_der_refraktiven_Augenchirurgie", "https://www.academia.edu/18153302/_Possible_role_of_alkylphosphocholines_in_retinal_reattachment_surgery_", "https://independent.academia.edu/KirstenEibl", "https://www.academia.edu/18153302/_Possible_role_of_alkylphosphocholines_in_retinal_reattachment_surgery_", "https://www.academia.edu/4742467/Multifokale_Elektroretinographie_mfERG_", "https://independent.academia.edu/MimatiBach", "https://www.academia.edu/4742467/Multifokale_Elektroretinographie_mfERG_", "https://www.academia.edu/49876677/Schleimhautpemphigoid_mit_okul%C3%A4rer_Beteiligung", "https://independent.academia.edu/GerdGeerling", "https://www.academia.edu/49876677/Schleimhautpemphigoid_mit_okul%C3%A4rer_Beteiligung", "https://www.academia.edu/26375810/M%C3%B6gliche_Rolle_von_Alkylphosphocholinen_bei_der_Ablatio_Chirurgie", "https://independent.academia.edu/GeoffreyLewis2", "https://www.academia.edu/26375810/M%C3%B6gliche_Rolle_von_Alkylphosphocholinen_bei_der_Ablatio_Chirurgie", "https://www.academia.edu/24790714/Historische_Einleitung", "https://ucalgary.academia.edu/FrankStahnisch", "https://www.academia.edu/24790714/Historische_Einleitung", "https://www.academia.edu/47998312/Funktionelle_Glaukomdiagnostik", "https://independent.academia.edu/CarlErb", "https://www.academia.edu/47998312/Funktionelle_Glaukomdiagnostik", "https://www.academia.edu/19175628/Navigierte_Netzhautlasertherapie", "https://lmu-munich.academia.edu/MarcusKernt", "https://www.academia.edu/19175628/Navigierte_Netzhautlasertherapie", "https://www.academia.edu/17629035/Perspektive_Tissue_engineering_bei_RPE_Transplantation_in_AMD", "https://independent.academia.edu/PhilipHuie", "https://www.academia.edu/17629035/Perspektive_Tissue_engineering_bei_RPE_Transplantation_in_AMD", "https://www.academia.edu/18983081/Standardisierte_Descemet_Membran_Endothelkeratoplastik_DMEK_", "https://independent.academia.edu/KonstantinosDroutsas", "https://mhn.academia.edu/MartinDirisamer", "https://independent.academia.edu/PeterCiechanowski", "https://www.academia.edu/18983081/Standardisierte_Descemet_Membran_Endothelkeratoplastik_DMEK_", "https://www.academia.edu/9389947/Amnion_Limbus_Transplantation_zur_Oberfl%C3%A4chenrekonstruktion_nach_schwerer_Ver%C3%A4tzung_und_Verbrennung", "https://ecomedicine.academia.edu/WolfgangMUSS", "https://www.academia.edu/9389947/Amnion_Limbus_Transplantation_zur_Oberfl%C3%A4chenrekonstruktion_nach_schwerer_Ver%C3%A4tzung_und_Verbrennung", "https://www.academia.edu/7751152/Akantham%C3%B6benkeratitis_bei_Kontaktlinsentr%C3%A4gern_in_der_Patientenpopulation_der_Augenklinik_Debrecen", "https://unsyiah.academia.edu/JunyModis", "https://www.academia.edu/7751152/Akantham%C3%B6benkeratitis_bei_Kontaktlinsentr%C3%A4gern_in_der_Patientenpopulation_der_Augenklinik_Debrecen", "https://www.academia.edu/24478294/Enzymatischer_Nachweis_der_Tiefenabh%C3%A4ngigkeit_der_Vernetzungswirkung_von_Riboflavin_UVA_an_der_Hornhaut", "https://independent.academia.edu/ESpoerl", "https://www.academia.edu/24478294/Enzymatischer_Nachweis_der_Tiefenabh%C3%A4ngigkeit_der_Vernetzungswirkung_von_Riboflavin_UVA_an_der_Hornhaut", "https://www.academia.edu/14361112/Endophthalmitisrate_mit_und_ohne_topische_postoperative_Antibiotikagabe_nach_intravitrealer_Avastin_Injektion", "https://uni-marburg.academia.edu/CarstenMeyer", "https://www.academia.edu/14361112/Endophthalmitisrate_mit_und_ohne_topische_postoperative_Antibiotikagabe_nach_intravitrealer_Avastin_Injektion", "https://www.academia.edu/21341457/Heilungsverlauf_und_Komplikationen_nach_Augenmuskeloperationen", "https://independent.academia.edu/MichaelGraf2", "https://www.academia.edu/21341457/Heilungsverlauf_und_Komplikationen_nach_Augenmuskeloperationen", "https://www.academia.edu/6882026/Botulinumtoxin_Die_Dosis_macht_das_GiftEin_historischer_Abriss", "https://meduni-graz.academia.edu/carlhomann", "https://www.academia.edu/6882026/Botulinumtoxin_Die_Dosis_macht_das_GiftEin_historischer_Abriss", "https://www.academia.edu/49685825/Ein_Werkstattbericht_aus_dem_Arbeitskreis_Psycho_Ophthalmologie", "https://hs-magdeburg.academia.edu/GabrieleHelgaFranke", "https://www.academia.edu/49685825/Ein_Werkstattbericht_aus_dem_Arbeitskreis_Psycho_Ophthalmologie", "https://www.academia.edu/34628751/Das_Paradox_Ozon_Ozon_ist_ebenso_ein_starkes_Oxidant_wie_ein_Arzneimittel", "https://unisi.academia.edu/EmmaBorrelli", "https://www.academia.edu/34628751/Das_Paradox_Ozon_Ozon_ist_ebenso_ein_starkes_Oxidant_wie_ein_Arzneimittel", "https://www.academia.edu/5811947/Die_Pflege_der_Medizin_und_Pharmazie_in_Regensburger_und_Oberpf%C3%A4lzer_Kl%C3%B6stern", "https://independent.academia.edu/ManfredKnedlik", "https://www.academia.edu/5811947/Die_Pflege_der_Medizin_und_Pharmazie_in_Regensburger_und_Oberpf%C3%A4lzer_Kl%C3%B6stern", "https://www.academia.edu/28256136/_Treatment_of_Acanthamoeba_keratitis_possibilities_problems_and_new_approaches_", "https://independent.academia.edu/JuliaWalochnik", "https://www.academia.edu/28256136/_Treatment_of_Acanthamoeba_keratitis_possibilities_problems_and_new_approaches_", "https://www.academia.edu/24801703/Ophthalmia_neonatorum_durch_Chlamydia_trachomatis", "https://independent.academia.edu/HerminiadeKaspar", "https://www.academia.edu/24801703/Ophthalmia_neonatorum_durch_Chlamydia_trachomatis", "https://www.academia.edu/Documents/in/Germany?f_loswp=50193414", "https://www.academia.edu/Documents/in/Humans?f_loswp=50193414", "https://www.academia.edu/Documents/in/Clinical_Sciences?f_loswp=50193414", "https://www.academia.edu/Documents/in/Optometry_and_Ophthalmology?f_loswp=50193414", "https://www.academia.edu/Documents/in/Ophthalmic_Solutions?f_loswp=50193414", "https://www.academia.edu/Documents/in/Neurosciences?f_loswp=50193414", "https://www.academia.edu/Documents/in/Serum_albumin?f_loswp=50193414", "https://www.academia.edu/about", "https://www.academia.edu/press", "https://medium.com/academia", "https://www.academia.edu/Directory/People", "https://www.academia.edu/Directory/Papers", "https://www.academia.edu/topics", "https://www.academia.edu/Jobs", "https://www.academia.edu/hiring", "https://support.academia.edu/", "https://www.academia.edu/Documents/in/Physics", "https://www.academia.edu/Documents/in/Chemistry", "https://www.academia.edu/Documents/in/Biology", "https://www.academia.edu/Documents/in/Health_Sciences", "https://www.academia.edu/Documents/in/Ecology", "https://www.academia.edu/Documents/in/Earth_Sciences", "https://www.academia.edu/Documents/in/Cognitive_Science", "https://www.academia.edu/Documents/in/Mathematics", "https://www.academia.edu/Documents/in/Computer_Science", "https://www.academia.edu/terms", "https://www.academia.edu/privacy", "https://www.academia.edu/copyright"]}